FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2781065437> ?p ?o ?g. }

• W2781065437 endingPage "14848" @default.
• W2781065437 startingPage "14828" @default.
• W2781065437 abstract "// Stephen Hyter 1 , Jeff Hirst 1 , Harsh Pathak 1, 2 , Ziyan Y. Pessetto 1 , Devin C. Koestler 2, 3 , Rama Raghavan 3 , Dong Pei 2, 3 and Andrew K. Godwin 1, 2 1 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA 2 University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA 3 Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA Correspondence to: Andrew K. Godwin, email: agodwin@kumc.edu Keywords: auranofin; AUY922; ovarian; gene signature; TCGA Received: September 01, 2017     Accepted: December 13, 2017     Epub: December 26, 2017     Published: March 13, 2018 ABSTRACT There is a lack of personalized treatment options for women with recurrent platinum-resistant ovarian cancer. Outside of bevacizumab and a group of poly ADP-ribose polymerase inhibitors, few options are available to women that relapse. We propose that efficacious drug combinations can be determined via molecular characterization of ovarian tumors along with pre-established pharmacogenomic profiles of repurposed compounds. To that end, we selectively performed multiple two-drug combination treatments in ovarian cancer cell lines that included reactive oxygen species inducers and HSP90 inhibitors. This allowed us to select cell lines that exhibit disparate phenotypes of proliferative inhibition to a specific drug combination of auranofin and AUY922. We profiled altered mechanistic responses from these agents in both reactive oxygen species and HSP90 pathways, as well as investigated PRKCI and lncRNA expression in ovarian cancer cell line models. Generation of dual multi-gene panels implicated in resistance or sensitivity to this drug combination was produced using RNA sequencing data and the validity of the resistant signature was examined using high-density RT-qPCR. Finally, data mining for the prevalence of these signatures in a large-scale clinical study alluded to the prevalence of resistant genes in ovarian tumor biology. Our results demonstrate that high-throughput viability screens paired with reliable in silico data can promote the discovery of effective, personalized therapeutic options for a currently untreatable disease." @default.
• W2781065437 created "2018-01-05" @default.
• W2781065437 creator A5003443127 @default.
• W2781065437 creator A5006461405 @default.
• W2781065437 creator A5015247627 @default.
• W2781065437 creator A5020195433 @default.
• W2781065437 creator A5033625395 @default.
• W2781065437 creator A5046887908 @default.
• W2781065437 creator A5058265159 @default.
• W2781065437 creator A5084248888 @default.
• W2781065437 date "2017-12-26" @default.
• W2781065437 modified "2023-10-16" @default.
• W2781065437 title "Developing a genetic signature to predict drug response in ovarian cancer" @default.
• W2781065437 cites W1529356222 @default.
• W2781065437 cites W1748709546 @default.
• W2781065437 cites W1910229223 @default.
• W2781065437 cites W1967220865 @default.
• W2781065437 cites W1967438857 @default.
• W2781065437 cites W1968922576 @default.
• W2781065437 cites W1969361257 @default.
• W2781065437 cites W1973117787 @default.
• W2781065437 cites W1974257291 @default.
• W2781065437 cites W1976022788 @default.
• W2781065437 cites W1983592978 @default.
• W2781065437 cites W1984799406 @default.
• W2781065437 cites W1988883152 @default.
• W2781065437 cites W1989654707 @default.
• W2781065437 cites W1996311090 @default.
• W2781065437 cites W1997338647 @default.
• W2781065437 cites W2008546211 @default.
• W2781065437 cites W2011186822 @default.
• W2781065437 cites W2014154914 @default.
• W2781065437 cites W2015015957 @default.
• W2781065437 cites W2016226316 @default.
• W2781065437 cites W2028797524 @default.
• W2781065437 cites W2039045990 @default.
• W2781065437 cites W2043398720 @default.
• W2781065437 cites W2048994607 @default.
• W2781065437 cites W2050313963 @default.
• W2781065437 cites W2053875585 @default.
• W2781065437 cites W2054990133 @default.
• W2781065437 cites W2060960815 @default.
• W2781065437 cites W2070967244 @default.
• W2781065437 cites W2071756286 @default.
• W2781065437 cites W2077945404 @default.
• W2781065437 cites W2078589933 @default.
• W2781065437 cites W2080284495 @default.
• W2781065437 cites W2086263152 @default.
• W2781065437 cites W2096439168 @default.
• W2781065437 cites W2098682850 @default.
• W2781065437 cites W2100214216 @default.
• W2781065437 cites W2102141802 @default.
• W2781065437 cites W2103196126 @default.
• W2781065437 cites W2106787323 @default.
• W2781065437 cites W2106833357 @default.
• W2781065437 cites W2106930503 @default.
• W2781065437 cites W2111501574 @default.
• W2781065437 cites W2112740677 @default.
• W2781065437 cites W2112932498 @default.
• W2781065437 cites W2117501436 @default.
• W2781065437 cites W2118851638 @default.
• W2781065437 cites W2121604817 @default.
• W2781065437 cites W2123696077 @default.
• W2781065437 cites W2125321800 @default.
• W2781065437 cites W2126404583 @default.
• W2781065437 cites W2131120911 @default.
• W2781065437 cites W2131593373 @default.
• W2781065437 cites W2131994307 @default.
• W2781065437 cites W2134954733 @default.
• W2781065437 cites W2137132470 @default.
• W2781065437 cites W2138122497 @default.
• W2781065437 cites W2138125759 @default.
• W2781065437 cites W2148406780 @default.
• W2781065437 cites W2154416737 @default.
• W2781065437 cites W2158485828 @default.
• W2781065437 cites W2162547088 @default.
• W2781065437 cites W2163357890 @default.
• W2781065437 cites W2166550586 @default.
• W2781065437 cites W2166999544 @default.
• W2781065437 cites W2168384927 @default.
• W2781065437 cites W2170573493 @default.
• W2781065437 cites W2181377275 @default.
• W2781065437 cites W2186858139 @default.
• W2781065437 cites W2190767857 @default.
• W2781065437 cites W2302476265 @default.
• W2781065437 cites W2308074142 @default.
• W2781065437 cites W2308791360 @default.
• W2781065437 cites W2328760560 @default.
• W2781065437 cites W2420531478 @default.
• W2781065437 cites W2551212791 @default.
• W2781065437 cites W2555631900 @default.
• W2781065437 cites W2577081087 @default.
• W2781065437 cites W2604421342 @default.
• W2781065437 cites W2620367814 @default.
• W2781065437 cites W2734284818 @default.
• W2781065437 cites W4210407906 @default.
• W2781065437 doi "https://doi.org/10.18632/oncotarget.23663" @default.
• W2781065437 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5871081" @default.

• next